Overview of CosmoCol Paediatric

CosmoCol Paediatric is a specific pharmaceutical preparation classified as an osmotically acting laxative, which means it works by softening the stool to provide relief from the difficulties associated with chronic constipation in children aged two to eleven years. This medicine is legally supplied as a Prescription-Only Medicine (POM) in the UK, reflecting its use in managing persistent conditions in a paediatric target group.

Property	Description
Active ingredient	Macrogol 3350
Form	Powder for oral solution (sachet)
Pharmacological class	Osmotically acting laxative
General purpose	Relief from chronic constipation
Origin	Synthetic polymer (Macrogol 3350)

What Type of Medicine is CosmoCol Paediatric?

CosmoCol Paediatric is classified as a laxative belonging to the specific pharmacological class of osmotically acting agents. Unlike stimulating laxatives that directly increase the muscular contractions of the bowel, this medicine operates based on a physical principle to restore natural bowel function. Macrogol 3350 is a standard agent in this class for paediatric use, providing a consistent approach to managing long-term constipation in children. The product's specific formulation is designed for use in a paediatric target group and is positioned as an electrolyte-balanced solution.

Macrogol 3350: Composition and Origin

The main active ingredient in the preparation is Macrogol 3350, a synthetic polymer also known as Polyethylene glycol 3350. This compound is considered an inert substance because it is virtually unabsorbed from the gut, ensuring its action is localized. CosmoCol Paediatric is a combination product because it also contains a balanced blend of essential electrolytes, including sodium chloride, potassium chloride, and sodium hydrogen carbonate. This electrolyte blend is included in Macrogol 3350 preparations to help ensure the patient's hydration balance is maintained during treatment.

General Purpose: How Does this Laxative Help?

The medicine’s general purpose is to provide comfortable relief by initiating the physical mechanism of water retention in the bowel. Macrogol 3350 attracts and holds water in the gut lumen, which increases the water content and bulk of the intestinal material. This process achieves direct stool softening and increases the volume of the stool, naturally stimulating colon motility. These formulations are effective because they work via the physical presence of the polymer, increasing the volume of colonic fluid. This means the medicine works physically, making stools softer and easier to pass. A typical use scenario involves helping a child who is experiencing persistent difficulty or discomfort when passing stools, providing clinically recognized relief.

Regulatory References

NICE Guideline CG99: Constipation in children and young people

What side effects are possible with CosmoCol Paediatric?

Possible side effects and safety information

The safety profile for CosmoCol Paediatric, which contains Macrogol 3350 with electrolytes, is documented in official regulatory sources. Adverse reactions are classified according to standard frequency categories, with the most commonly reported effects involving the gastrointestinal system.

Frequency-Classified Adverse Reactions

Side effects are officially classified into System-Organ Classes (SOCs), primarily affecting Gastrointestinal Disorders, Immune System Disorders, and Skin and Subcutaneous Tissue Disorders.

Frequency	Examples of Officially Documented Adverse Reactions
Very Common (≥ 1/10)	Abdominal pain, stomach rumbling (borborygmi).
Common (≥ 1/100 to < 1/10)	Diarrhoea, vomiting, nausea, anorectal discomfort.
Uncommon (≥ 1/1,000 to < 1/100)	Abdominal distension (bloating), flatulence.
Rare (≥ 1/10,000 to < 1/1,000)	Allergic reactions, including anaphylactic reaction.
Not Known	Headache, peripheral oedema, and electrolyte disturbances.

Serious Adverse Reactions and Safety Constraints

The regulatory safety profile notes the potential for serious allergic reactions (such as angioedema and difficulty breathing) and highlights the risk of seizures in post-marketing reports, which are often associated with severe electrolyte abnormalities. Symptoms indicating fluid or electrolyte shifts, such as peripheral swelling or increasing fatigue, are listed as requiring immediate cessation of treatment.

Official documents indicate that diarrhoea and loose stools are often observed during the high-dose regimen for faecal impaction, which can usually be resolved by a reduction in dose. A specific safety restriction noted in regulatory documents is that Macrogol is documented to counteract the thickening effect of starch-based food thickeners, a critical constraint for patients with swallowing difficulties. Furthermore, the fluid content of the reconstituted solution is officially stated not to replace regular fluid intake; adequate fluid intake must be maintained.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Macrogol 3350 with electrolytes defines the primary clinical manifestations as excessive diarrhoea, often accompanied by severe abdominal distension and vomiting. The most serious outcomes documented by regulatory authorities are the resultant systemic effects: electrolyte disturbances and dehydration. These events can lead to a derangement of the water balance and acid and base balance, defining the severity of the overdose.

Regulatory guidance explicitly mandates that medical help must be sought immediately when an overdose is suspected or when symptoms indicative of severe fluid or electrolyte shifts occur. The required emergency action is to stop the medication immediately and seek immediate medical attention or contact a Poison Control Center right away.

Management is strictly defined as symptomatic and supportive treatment, as no specific antidote is documented in the labeling. This supportive approach involves the correction of electrolyte disturbances and adequate fluid replacement. Medical monitoring of serum electrolytes and pH is required to manage the systemic consequences of severe overdose. Population-specific notes indicate a higher risk for water-electrolyte balance disorders in the elderly and patients with impaired renal function.

Therapeutic Uses of CosmoCol Paediatric

CosmoCol Paediatric is commonly used in clinical settings that involve acute or unstable symptom patterns associated with difficulty in stool passage in children. Macrogols are considered relevant for managing chronic constipation in this patient group.

This medicine is generally used for the long-term management of chronic constipation and the intensive, short-term support in addressing faecal impaction. It is relevant for managing symptoms that create noticeable interference with a child's daily stability, such as pain on defaecation, straining, and associated abdominal discomfort. The medication is generally used for managing symptoms that interfere with daily comfort, such as infrequent and hard stools, and is applied to support the process of easing hard stool consistency. This helps patients cope more steadily with difficult episodes and supports comfortable, regular bowel function.

“This medication is applied across domains where additional symptomatic support is needed to assist with difficult episodes.”

Quick Fact: Relief for Straining and Pain on Defaecation The medicine is relevant for easing symptoms related to the physical mechanics of stool passage, assisting with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

National NHS Clinical Pathway for Children

Eligibility and Restrictions for Use

Eligibility for CosmoCol Paediatric

The eligibility profile for CosmoCol Paediatric is strictly defined by regulatory authorities based on age and the presence of specific comorbidities.

Who Can Use the Medicine

Indication	Approved Age Group (Official Label)
Chronic Constipation	Children aged 2 to 11 years
Faecal Impaction	Children aged 5 years or above (up to 11 years)

Patients aged 12 years and above are directed to use the non-paediatric (adult) formulation. The active substance can be used during pregnancy and breastfeeding by the caregiver, as minimal systemic exposure is anticipated.

Who Cannot Use the Medicine (Contraindications)

The medicine is contraindicated and must not be used in children with certain acute or severe gastrointestinal conditions, including intestinal obstruction (ileus), intestinal perforation or a risk of perforation, and toxic megacolon.

It is also prohibited for patients with severe inflammatory bowel diseases, such as ulcerative colitis or Crohn's disease, or those with known hypersensitivity to Macrogol 3350 or any of the product’s components.

Use for faecal impaction is not recommended for children with renal insufficiency or impaired cardiovascular function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for CosmoCol Paediatric, which contains Macrogol 3350 with electrolytes, is structured around its action within the gastrointestinal tract, as the active ingredient is virtually unabsorbed into the bloodstream.

Drug–Drug and Timing Restrictions

Co-administration with other oral medicines may result in a transient reduction in absorption and drug exposure. This is officially documented as a pharmacokinetic interaction caused by the increased rate of gastrointestinal transit induced by the laxative effect. The regulatory label cites isolated reports of decreased efficacy for certain concomitantly administered oral medicines, such as anti-epileptic agents.

To mitigate the risk of reduced exposure, a mandatory administration-timing rule is specified: other medicines must not be taken orally during the window of one hour before, during, and one hour after the administration of CosmoCol Paediatric. This requirement is especially relevant when high doses are used, such as during treatment for faecal impaction.

Drug–Substance and Physicochemical Incompatibility

A specific physicochemical interaction exists with products used to modify fluid consistency. Macrogol 3350 is documented to counteract the thickening effect of starch-based food thickeners, leading to the liquefaction of thickened preparations. This restriction is clinically significant for the population of patients who rely on thickened fluids due to difficulty swallowing or an impaired gag reflex.

Mechanism of Action

CosmoCol Paediatric exerts its action entirely through physical-chemical mechanisms localized within the gut. The core effect relies on the osmotic activity of its main component, Macrogol 3350 (Polyethylene Glycol).

Osmotic Water Sequestration

Macrogol 3350 is a non-absorbed polymer that creates an osmotic gradient by binding and retaining water molecules in the colon. This mechanism causes a sustained influx of water into the faecal mass, leading to the rehydration and softening of the stool, a process that facilitates the movement of contents.

️ Bulk-Induced Peristaltic Activation

The water retention increases the volume and physical bulk of the faeces. This volumetric expansion gently distends the colon wall, indirectly stimulating the peristaltic reflex via local stretch receptors. This action promotes the natural, coordinated contractions that propel the softened contents through the bowel.

️ Electrolyte Stabilization and Homeostasis

The inclusion of essential electrolytes (e.g., sodium and potassium) acts as a crucial mechanistic stabilizer. By maintaining an iso-osmotic state within the gut lumen, the formulation ensures that the osmotic draw results in minimal net transfer of fluid and ions from the body's systemic circulation, preserving the stability of serum electrolyte concentrations.

Dosage and Administration Information

How to Use CosmoCol Paediatric

This section outlines the administration of CosmoCol Paediatric, which is intended for oral use only as a reconstituted solution.

Dosing by Clinical Scenario

Indication	Age Group	Starting Regimen	Dose Adjustment and Maximum
Chronic Constipation	2 to 11 years	Starts with 1 sachet daily (2–6 years) or 2 sachets daily (7–11 years).	Adjustment occurs every second day. The normal maximum daily dose is 4 sachets.
Faecal Impaction	5 to 11 years	Incremental schedule over 7 days, beginning with 4 sachets on Day 1.	Dose increases up to a maximum of 12 sachets daily (Days 5–7).

Preparation and Timing Instructions

Preparation: The contents of each sachet must be dissolved in 62.5 ml (approximately one-quarter of a glass) of water. The reconstituted solution can be stored, covered, and refrigerated for up to 24 hours.

Frequency and Duration: The daily dose for chronic constipation may be taken once daily or in divided doses. For faecal impaction, the total dose must be divided and consumed over a 12 hour period. Chronic treatment is typically designated as long-term (e.g., 6–12 months), while impaction treatment is strictly short-term and must cease upon successful disimpaction.

Procedural Constraint: The medicine can be administered at any time, irrespective of food intake. To ensure proper absorption of other medications, solid oral medicines should not be taken within 1 hour before or after administering this solution. The fluid content used for reconstitution does not replace regular daily fluid intake.

Recent Clinical Evidence

Research Evidence / Overview of Studies for CosmoCol Paediatric

Evidence for Use in Chronic Functional Constipation

This section summarizes the body of evidence, primarily consisting of Randomized Controlled Trials (RCTs) and systematic reviews, that examined whether use of this medicine was associated with changes in core functional outcomes, such as bowel movement frequency and stool consistency in children with chronic constipation aged 2 to 11 years.

Research has extensively examined the use of Macrogol 3350 with electrolytes in children with chronic functional constipation, a condition marked by functional limitations. The most common research design used is the Randomized Controlled Trial (RCT), where the medicine was evaluated against a placebo or other active comparators. Studies monitored outcomes related to systemic or functional imbalance, such as the weekly frequency of defaecation, and stool consistency, using standardized scales. Research provides context but not individual predictions about how any specific child will respond.

However, certain limitations are noted in the scientific literature. While many high-quality RCTs exist, there is limited information for long-term outcomes and the durability of effects beyond six to twelve months of use are not fully established. Some early systematic reviews observed heterogeneity (differences) in trial designs, meaning evidence quality varies across studies to some extent.

Evidence for Use in Faecal Impaction

This section will describe the research focused on the acute use of this medicine for managing faecal impaction, including comparative trials that assessed the successful disimpaction rate in paediatric patients against other acute interventions.

Research explored the role of Macrogol 3350 with electrolytes in conditions associated with acute or disruptive episodes, specifically for the treatment of faecal impaction (severe, persistent constipation). Studies are often designed as Comparative Trials, where the oral solution was studied against traditional rectal interventions, such as enemas, in children typically aged five years and older. Studies monitored outcomes describing episodic or acute changes, focusing on the successful disimpaction rate achieved within a short time interval.

Findings describe patterns observed in the studies related to the measured outcomes of the impaction phase during the treatment period. Comparative evidence explores whether outcomes measured during the study period were consistent with those reported for conventional rectal treatments. Research provides insight into short-term changes in this acute setting.

Macrogol 3350 vs. Other Osmotic Laxatives (Comparator Research)

Numerous studies have explored how Macrogol 3350 with electrolytes compares to other widely used in research osmotic laxatives, such as lactulose. This comparative research examined patient-reported outcomes describing perceived discomfort and functional changes in children with chronic functional constipation. Research examined the outcomes for measured stool consistency and frequency when the Macrogol formulation was compared to lactulose. Research highlights that the findings across various studies were observed in some studies to be aligned, but the results apply only to the populations studied under the specific conditions of the trials.

What is Still Uncertain About the Research Landscape

The scientific literature highlights several areas where research is ongoing or where certainty remains low. One key area is the lack of extensive, high-quality, randomized evidence examining use over very long durations, meaning long-term effects are not fully established. Additionally, evidence quality varies across studies due to differences in how Macrogol formulations (with versus without electrolytes) were observed in different early trials. Overall, evidence highlights what is known — and what is still uncertain — and findings describe group patterns, not personal outcomes.

Key Studies & References Constipation in children and young people: diagnosis and management (NICE Guideline NG62)

Frequently Asked Questions (FAQ)

Common questions about CosmoCol Paediatric (FAQ)

Q: Is CosmoCol Paediatric the same thing as Movicol Paediatric?

A: Official regulatory documents show that the active ingredient in CosmoCol Paediatric is Macrogol 3350 with electrolytes. The final chemical composition aligns with other similar macrogol products, such as Movicol Paediatric. These products share the same classification and mechanism of action, according to regulatory documents.

Q: How quickly should I expect to see the medicine working?

A: The official prescribing information does not provide a specific timeframe for the first bowel movement. However, for the treatment to be successful, the patient's stools should gradually become softer and bowel movements should become more regular. If very loose stools or diarrhea occur, official guidance notes that a dose reduction may be needed.

Q: Does this medicine cause dependence if used for weeks?

A: Official product information describes the treatment for chronic constipation as typically prolonged, often lasting 6 to 12 months. The official guidance for chronic constipation involves a gradual stopping of treatment when successful, and resuming if the condition recurs. This is in the context of prolonged treatment for a chronic condition.

Q: Can children with celiac disease use this medicine?

A: Official composition lists for the medication do not typically include gluten or lactose among the primary components. Flavoured versions do list other excipients like sorbitol and maltodextrin. The ingredient list is published in the Patient Information Leaflet, suggesting the product does not contain the specified allergens, which aligns with the official ingredient lists.

Q: If a dose is missed, what is generally advised in the official guidelines?

A: According to the official guidelines, if a dose is forgotten, official guidelines advise against taking a double dose to compensate. The advice is simply to continue with the treatment schedule and take the next dose at the usual time.

Q: What should be done if the powder doesn't fully dissolve in the liquid?

A: Regulatory guidance states that the powder must be stirred in the specific amount of water until the solution is clear. If the powder does not dissolve completely right away, continuing to stir until it is clear is necessary to ensure the full dose of medicine is administered correctly.

Q: Are there any known interactions with commonly prescribed asthma medicines?

A: Official safety information warns that this medicine can transiently reduce the absorption and efficacy of other oral medicines. While asthma medicines are not cited as a specific example, the regulatory risk applies generally to any medicine taken by mouth. The recommended precaution to mitigate this risk involves separating the administration of the solution from all other oral medicines by at least one hour.

Q: Is the medication flavor-free or does it come in different flavors?

A: Official product information indicates that CosmoCol Paediatric is available in a Plain (unflavored) option. It is also available in different flavors, such as Orange, Lemon, and Lime.

Q: Does CosmoCol Paediatric contain sugar or artificial sweeteners?

A: The medication does not contain added sugar. However, the official excipient list typically includes the artificial sweetener saccharin sodium. Flavoured versions may also contain sorbitol, which is a type of sugar alcohol.

Q: Why is it important to follow the preparation instructions exactly?

A: Regulatory documents explain that the Macrogol 3350 works physically by binding with the correct amount of water. Following the instructions to dissolve the powder in the specific volume of water is essential to ensure the medicine works correctly.

Q: If a child vomits after taking the dose, what does the official guidance say?

A: Official guidance advises specific actions depending on the timing of the dose. If the child vomits less than 30 minutes after taking the medicine, guidance indicates that the same dose may be given again. If vomiting occurs more than 30 minutes after the dose, guidance indicates that another dose should not be given, and that the patient should wait until the next scheduled time.

Q: Does the medicine come with any measuring tools or scoop?

A: The medicine is packaged as a powder in pre-measured, single-use sachets. The required amount of water to dissolve the powder is typically measured by the caregiver using a standard quarter-glass or a measuring cup.

Q: Are there different package sizes available for the product?

A: Official product details indicate that the sachets are commonly packaged in various carton sizes. These may include boxes containing 20, 30, 50, 60, or 100 sachets. However, please note that not all available sizes may be marketed in every location.

Q: Can you mix CosmoCol Paediatric with milk or juice?

A: Official guidance states the powder must first be dissolved completely in the prescribed amount of water. The prepared solution may then be mixed with other liquids, such as juice or milk, to improve the taste.

Q: Are there any common food or drink restrictions while taking it?

A: Regulatory sources state that the medicine can be administered at any time of day, with or without food. The only official restriction relates to the use of starch-based food thickeners, as the medicine is documented to counteract their thickening effect.

Q: What does 'faecal impaction' mean, in simple terms?

A: Faecal impaction is officially defined in regulatory documents as a condition of refractory constipation with faecal loading. In simple terms, this means severe, persistent constipation where a hardened mass of stool remains in the rectum or colon.

Q: Is CosmoCol Paediatric safe to take with common vitamins or supplements?

A: The official product information states that the absorption of other oral medicines may be transiently reduced due to the increased rate of bowel transit. To mitigate this risk, the recommended precaution involves separating the administration of the solution from all oral products, including vitamins and supplements, by at least one hour.

Q: What is the longest period of continuous use that has been studied in clinical trials?

A: Official regulatory documents state that the safety and efficacy of CosmoCol Paediatric have been formally proven for continuous use up to a period of 3 months. While treatment for chronic constipation is often recommended for longer periods (6 to 12 months), the core evidence supports the initial 3-month duration.

Q: Is there a maximum number of days a patient should use it without a doctor's review?

A: The recommended maximum period for which the medicine's safety and efficacy are officially proven is 3 months. This timeframe is based on the documented period for which safety and efficacy have been proven.

Q: What are the non-active ingredients listed in the product?

A: According to the official list of excipients, the non-active ingredients typically include various components such as colloidal anhydrous silica and the sweetener saccharin sodium. The flavourings also contribute to the non-active ingredients and may contain other substances like maltodextrin, mannitol, and sorbitol.

Q: What is the difference between chronic constipation and occasional constipation?

A: Official product information defines chronic constipation as a condition that typically requires prolonged treatment, often lasting 6 to 12 months. Occasional or short-term constipation is not a listed approved indication for this specific medicine.

Q: What warnings are included about use in very young babies or infants?

A: Regulatory documents contain specific age restrictions. The product is officially not recommended for the treatment of chronic constipation in children under 2 years of age. Similarly, it is not recommended for faecal impaction in children under 5 years of age.

Q: Do the ingredients contain any common allergens like gluten or lactose?

A: The standard composition information from regulatory agencies does not list the common allergens gluten or lactose among the primary ingredients. The full list of ingredients is published in the Patient Information Leaflet for caregivers to check for other sensitivities.

How should CosmoCol Paediatric be stored and disposed of?

Storage Conditions

Unopened sachets of CosmoCol Paediatric powder must be stored below 25 C and should not be used past the expiry date on the carton and sachet. The medicine must be kept out of the sight and reach of children.

The Reconstituted Solution

Once the powder is dissolved in water, the resulting oral solution must be stored covered in a refrigerator (between 2 C and 8 C). The prepared solution is only stable for 24 hours and any unused solution remaining after that time must be discarded.

Disposal Instructions

Unused medicine or waste material, including solution exceeding the 24-hour limit, must not be thrown away via wastewater or general household waste. Disposal must be carried out in accordance with local requirements, typically by consulting a pharmacist for guidance on how to properly discard the medicine.

CosmoCol Paediatric